CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels
Portfolio Pulse from Benzinga Newsdesk
CymaBay Therapeutics announced new findings from a post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC). The data showed that treatment with seladelpar correlated with decreases in serum IL-31 and improvements in pruritus intensity.
June 21, 2023 | 7:23 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CymaBay Therapeutics' new findings from the Phase 3 ENHANCE study of seladelpar for PBC treatment show promising results, potentially boosting the company's stock.
The positive results from the Phase 3 ENHANCE study of seladelpar for PBC treatment indicate that the drug has potential to be effective in treating the condition. This could lead to increased demand for the drug and higher revenues for CymaBay Therapeutics, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100